Clinical and molecular characteristics of HER2-low-positive breast cancer: pooled analysis of individual patient data from four prospective, neoadjuvant clinical trials-Reference-Cited by-同舟云学术

Clinical and molecular characteristics of HER2-low-positive breast cancer: pooled analysis of individual patient data from four prospective, neoadjuvant clinical trials

Published:2021-08 Issue:8 Volume:22 Page:1151-1161
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Denkert Carsten,Seither Fenja,Schneeweiss Andreas,Link Theresa,Blohmer Jens-Uwe,Just Marianne,Wimberger Pauline,Forberger Almuth,Tesch Hans,Jackisch Christian,Schmatloch Sabine,Reinisch Mattea,Solomayer Erich F,Schmitt Wolfgang D,Hanusch Claus,Fasching Peter A,Lübbe Kristina,Solbach Christine,Huober Jens,Rhiem Kerstin,Marmé Frederik,Reimer Toralf,Schmidt Marcus,Sinn Bruno V,Janni Wolfgang,Stickeler Elmar,Michel Laura,Stötzer Oliver,Hahnen Eric,Furlanetto Jenny,Seiler Sabine,Nekljudova Valentina,Untch Michael,Loibl Sibylle

Funder

Stiftung Deutsche Krebshilfe

Publisher

Elsevier BV

Subject

Oncology

Reference28 articles.

1. HER2-positive breast cancer;Loibl;Lancet,2017

2. NSABP B-47/NRG oncology phase III randomized trial comparing adjuvant chemotherapy with or without trastuzumab in high-risk invasive breast cancer negative for HER2 by FISH and with IHC 1+ or 2;Fehrenbacher;J Clin Oncol,2020

3. The latest research and development into the antibody-drug conjugate, [fam-] trastuzumab deruxtecan (DS-8201a), for HER2 cancer therapy;Nakada;Chem Pharm Bull (Tokyo),2019

4. Trastuzumab duocarmazine in locally advanced and metastatic solid tumours and HER2-expressing breast cancer: a phase 1 dose-escalation and dose-expansion study;Banerji;Lancet Oncol,2019

5. Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive breast cancer previously treated with trastuzumab emtansine: a dose-expansion, phase 1 study;Tamura;Lancet Oncol,2019

Cited by 311 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. MRI-based machine learning radiomics for prediction of HER2 expression status in breast invasive ductal carcinoma;European Journal of Radiology Open;2024-12

2. crVDAC3 alleviates ferroptosis by impeding HSPB1 ubiquitination and confers trastuzumab deruxtecan resistance in HER2-low breast cancer;Drug Resistance Updates;2024-11

3. Understanding the spectrum of HER2 status in breast cancer: From HER2-positive to ultra-low HER2;Pathology - Research and Practice;2024-10

4. Landscape of HER2-low breast cancer: Insights from a six-year study on prevalence and clinicopathological characteristics;Annals of Diagnostic Pathology;2024-10

5. Characterization of HER2-Low Breast Tumors among a Cohort of Colombian Women;Cancers;2024-09-12